anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To efficiently obtain a red pigment which possesses excellent stability and other properties by strongly fixing a red beet dye onto a carrier selected from N,N-dialkylaminoethyl methacrylatemodified silk fibroin powders. SOLUTION: A carrier material selected from among N,Ndialkylaminoethyl methacrylate-modified silk fibroin powders (e.g. an N,N-dimethylaminoethyl methacrylate-modified silk fibroin powder) is provided. This carrier material is brought into contact with an aq. solvent (e.g. a mixed solvent composed of ethyl alcohol and water) contg. a red beet dye in the presence of a fixing promoter selected from among inorg. acids and org. acids (e.g. hydrochloric acid) to strongly fix the red beet dye onto the carrier material, thereby preparing a red pigment. A make-up cosmetic preparation prepd. by incorporating 0.01 to 50 pts.wt. red pigment into 100 pts.wt. basic compsn. of the cosmetic preparation has a vivid color tone, is excellent in adhesion to the skin, handle, and perspiration resistance, and is suitable as rouge, lipstick, manicure, pedicure and the like.
Participants received placebo tablets once a day for 12 weeks. At the end of 12 weeks participants were re-randomized to receive one of the two doses of elagolix (150 mg or 250 mg) QD for 12 weeks.
We present a case of a 75-year-old Asian woman with Guillain-Barré syndrome (GBS) who underwent a 1-month comprehensive rehabilitation training program supplemented by robot-assisted gait training (RAGT). GBS can lead to fatigue and prolonged bed rest, thereby further debilitating older patients. Although exercise intervention is recommended for GBS, a consensus regarding the appropriate intensity has yet to be established. Individualized strategies are required because older patients experience varying levels of fatigue and frailty. We used a technological adjunct to support comprehensive rehabilitation for GBS reconditioning in an older patient. To the best of our knowledge, research involving the use of an exoskeleton robotic device in the geriatric population with GBS is limited. Our case demonstrates the feasibility and safety of RAGT for improving lower limb muscle power and scores on the Barthel Index, Clinical Frailty Scale, and Instrumental Activities of Daily Living Scale at discharge from a geriatric ward.
The CVM-1118 ER Capsule will be orally administered BID or TID before meal in 28-day treatment cycles. Patients will receive 400, 600, 800 to 1,200 mg of CVM-1118 ER Capsule in sequential cohort based on safety and dose tolerability. A single-patient cohort per dose level (accelerated titration design) will be applied to the first two cohorts, 400 and 600 mg daily, and followed by the conventional 3+3 dose escalation design from the dose level of 800 mg/day. Within the first two cohorts, if any Grade 2 or greater toxicity at least possibly attributable to CVM-1118 ER capsule is reported in the first patient during first cycle, a single-patient cohort will be converted to conventional 3+3 study design once and expand to a minimum of 3 evaluable patients for assessment of toxicity within the first cycle. Dose escalation will occur until DLT occurs in 2 or more patients within a dose level. In any cohort, if 1 patient experiences a DLT, 3 additional patients will be enrolled to that dose level. If 2 or more patients experience a DLT, no further dose escalation will occur. Plasma pharmacokinetics samples will be collected at pre-determined time-points for all patients participating in the dose-escalation study.

This study will be completed and closed once the MTD is determined for CVM-1118 ER capsules. However, at the end of 4 cycles, it is recommended that some patients should continue receiving the clinical benefit from CVM-1118 ER capsules. Thus, patients may be continuously treated at the assigned dose level or next higher dose level provided it has been shown to be safe in a previously treated cohort by safety committee, until the treating physician feels the patient is no longer benefiting from the treatment, or CVM-1118 ER Capsule becomes commercially available, as applicable in the country in which the patient lives. In the event of unacceptable toxicity at a given dose, CVM-1118 can be reduced to the previous dose level or suggested lower dose by PI. If unacceptable toxicity persists despite 2 dose reductions, the patient should be removed from study.
Japan has the highest life expectancy worldwide. Older adults who experience economic insecurity may refrain from seeking medical consultation or using long-term care insurance, and these behaviors may increase the incidence and progression of frailty. This study conducted a cross-sectional survey to identify factors related to a sense of economic insecurity among older adults who participate in social activities, and identified support measures. In total, 1,351 older adults aged ≥65 years who had participated in social activities voluntarily completed an anonymous self-administered questionnaire. The questionnaire encompassed their physical, cognitive, social, and psychological conditions, and economic insecurity. We performed univariate analysis considering a sense of economic insecurity as the dependent variable, and conducted multiple logistic regression analysis (forced entry method) considering the independent variables with p<0.1 as the covariates. Among the 872 filled questionnaires, 717 were analyzed as they had no missing data with respect to the responses to survey questions (valid response rate was 53.1%). Analysis results showed that 43.6% of the older adults had a sense of economic insecurity, which was most common among those aged 75-84 years, accounting for 47.3%, followed by those aged 65-74 years accounting for 44.1%, and those aged ≥85 years accounting for 31.5% (p<0.05). The sense of economic insecurity was not associated with physical conditions, subjective symptoms of dementia, or social conditions; however, it grew with increased loneliness (OR: 1.71, 1.002-2.92, p = 0.049) and decreased with an increased subjective sense of well-being (OR: 0.86, 0.81-0.92, <0.001). Economic insecurity among older adults was not associated with physical, cognitive, or social aspects, as reported in previous studies. The survey respondents constituted older adults who participate in social activities. Maintaining interactions within the community, even in old age, may prevent loneliness and improve subjective health.
Arnica: May cause allergic reactions in sensitive individuals, especially if there is a history of ragweed allergies.

Bromelain: May increase the risk of bleeding in individuals taking anticoagulants or antiplatelet medications. Discontinue use two weeks before surgery.

Zinc and Vitamin C: Use cautiously in individuals with kidney disease or those prone to kidney stones. If you experience an allergic reaction or prolonged bleeding, discontinue use and seek medical attention immediately.

For use on the order of a licensed healthcare practitioner.

Call your doctor about side effects. To report side effects, call  PureTek Corporation at  1-877-921-7873.
Colorectal polyps serve as potential precursors of colorectal cancer and automating polyp segmentation aids physicians in accurately identifying potential polyp regions, thereby reducing misdiagnoses and missed diagnoses. However, existing models often fall short in accurately segmenting polyps due to the high degree of similarity between polyp regions and surrounding tissue in terms of color, texture, and shape. To address this challenge, this study proposes a novel three-stage polyp segmentation network, named Reverse Attention Feature Purification with Pyramid Vision Transformer (RAFPNet), which adopts an iterative feedback UNet architecture to refine polyp saliency maps for precise segmentation. Initially, a Multi-Scale Feature Aggregation (MSFA) module is introduced to generate preliminary polyp saliency maps. Subsequently, a Reverse Attention Feature Purification (RAFP) module is devised to effectively suppress low-level surrounding tissue features while enhancing high-level semantic polyp information based on the preliminary saliency maps. Finally, the UNet architecture is leveraged to further refine the feature maps in a coarse-to-fine approach. Extensive experiments conducted on five widely used polyp segmentation datasets and three video polyp segmentation datasets demonstrate the superior performance of RAFPNet over state-of-the-art models across multiple evaluation metrics.
The study group of the research consisted of 5-year-old students studying in kindergartens. The total number of students in kindergartens is 159 in the research area. Gpower 3.1.9.4 program was used to determine the sample size of the study. The sample size was determined as 42 ( 21 in the experimental and control groups) under a large effect size (0.80), an alpha value of 0.05 and a power level of 80%. It was decided to include a total of 52 students in the study by accepting a loss rate of approximately 20%.

Because it is known that it is important to promote physical activity at an early age, this study implemented interventions developed in accordance with the Coordinated Approach to Child Health Program, a program consisting of classroom, family, and student components. In the classroom component of the program, health education practices were prepared to teach children to identify, practice, and adapt physical activity habits to their lives through the classroom environment. In the family component of the program, there are interventions that ensure the participation of children, parents, and other family members to develop physical activity habits at home. Increasing physical activity in preschool children can be achieved by developing interventions that are fun and encourage children to be physically active in a structured classroom setting that promotes gross motor skills and moderate to vigorous physical activity during kindergarten and recess. In this study, a six-week program consisting of nurse, teacher, and family components developed in accordance with the Coordinated Approach to Child Health in Preschool Children program was implemented twice a week to evaluate its effects on physical activity in preschool children and its effectiveness in increasing physical activity.

The interventions averaged 60 minutes per week. Prior to implementation, school administrators and teachers were interviewed and informed about the purpose of the research and the implementation process. To inform parents and students about the research, the informed consent form and parent questionnaire were sent to parents in a sealed envelope and collected from students by teachers the next day. Informed consent was obtained by explaining the purpose and procedure of the study to the students whose parents had given their consent, and they were asked to complete the data collection instruments through the classroom teacher (pre-test). The post-test was administered 2 weeks after the completion of the study. The pre-test and post-test were administered by the teachers and the height-weight measurements were done by the nurse. No intervention was applied to the control group except for the physical activities they perform in their daily lives. Data collection instruments were administered to the control group in a similar manner and at the same time as the experimental group. The primary outcomes expected from the study are anthropometric measurements and physical activity levels. The research data was collected using the parent questionnaire developed by the researchers based on the literature and anthropometric measurements.
Mixtures of cyanoacrylate monomers and radiopaque additives stable to the monomer produce radiopaque compositions useful in surgical and other applications. The additives useful in the compositions are triiodophenol, tetraiodethylene, iodoform and mixtures thereof. When Iodoform is included in the compositions, at least an equal molar amount of triiodophenol should also be included. The compositions include between 0.5 and 11 mole percent iodine and preferably contain at least 4 mole percent iodine. Inhibitors such as SO 2  and hydroquinone may also be included. The compositions are preferably compounded with cyanoacrylate monomers of greater than 98-percent purity.
Patents undergo collection of blood and stool samples at baseline, 7 days after letrozole monotherapy treatment, and at completion of each cycle, urine samples at baseline and completion of each cycle, and saliva samples at baseline. Patients also undergo collection of blood and urine samples at disease progression. Biopsy samples are analyzed for genetic profile via genome sequencing and RNA sequencing. Biopsy samples are also used for the generation of xenograft mice model.
This is a multicenter, cross-sectional study involving 200 consecutive patients with a diagnosis of idiopathic PD.

We will collect demographic data such as age, sex and education, and clinical features encompassing age at onset, disease duration, antiparkinsonian treatment, and levodopa-equivalent daily dose (LEDD). Patients will undergo a clinical examination in which we will record the Hoehn and Yahr scale (H\&amp;Y) and Movement Disorders Unified Parkinson\&#39;s Disease Rating Scale (MDS-UPDRS) part I-II- III (in ON state) and IV, and Montreal Cognitive Assessment (MoCA). The answers to the NoMoFA will be obtained giving the self-administered questionnaire to patients during regular follow-up visits. The NoMoFA Questionnaire has a total of 27 items with a total maximum possible score for the NoMoFA of 81 points (27 x 3). To evaluate the stability of the Italian version of the NoMoFA (test-retest reliability), a group of 60 patients will repeat the scale 14 days after the first evaluation.

We will establish a translation team composed of movement disorders specialists who are native speakers of the designated language and fluent in English. As word-for-word translations can be misleading, cultural difference between English and Italian will be taken into account. After translation, a different independent group with same competencies of the first translating team will perform a back-translation. The back-translated version of the rating scale will be compared to the original English version. The translation and back-translation team members in a revised document will fully resolve unclear concepts or ambiguities between the original and back-translated English editions. Before the validation phase, a so-called 'cognitive pretesting' will be performed by submitting the provisional translated scale to 10 PD patients by 2 evaluators external to the translator team. Then, evaluators\&#39; and subjects\&#39; responses will be integrated into the revisions and retested until all major problems are resolved. Once the translation and cognitive pretesting stages are completed, the translated scale is field-tested in a sample of native speakers of the language of the translated scale (validation).
Subjects randomised to receive Octreotide were administered with Octreotide (Sandostatin LAR™) 40mg 7 days before the start of treatment with Lapatinib and Capecitabine and again 28 days later. All subjects received treatment with Lapatinib 1250milligram (mg) once daily and Capecitabine 1000 milligram/square meter (mg/m\^2) twice daily until disease progression. Lapatinib was given every day; Capecitabine was given in 3 week cycles of two weeks treatment followed by one week off treatment. SANDOSTATIN™ is a trademark of Novartis.
Sham or simulated dry needling. + usual care. Subjects will receive a total of 4 sessions of sham ultrasound-guided dry needling over 4 weeks, one per week.
All patients will undergo MRE in year 1, and this test may not be recommended in all patients. Year 1 MRE is the only procedure that may be performed outside of clinical practice.
PURPOSE:To provide the titled preparation containing bis[cyclo(histidylhistidine)] copper salt complex as an active component, effective in removing active oxygen and preventing the formation of lipid peroxide in the living body, exhibiting prolonged effect by oral administration and useful as a remedy for hepatic diseases, etc., having low side effect. CONSTITUTION:The objective preparation contains a bis[cyclo(histidylhistidine)] copper salt complex as an active component. The above active component is formed in the form of tablet, granule, etc., together with a conventional drug preparation carrier. The content of the active component compound is usually about 1-70wt.%, preferably about 1-30wt.% in the whole composition. The amount of the active component compound in the administration unit is preferably about 0.1-100mg. It may be administered in the form of parenteral drug e.g. injection according to the symptom. An example of the above active component compound is bis[cyclo(histidylhistidine)] copper (II) (ClO4<->)2.
Oncogene-driven expression and activation of receptor tyrosine kinases promotes tumorigenesis and contributes to drug resistance. Increased expression of the kinases discoidin domain receptor 2 (DDR2), RET Proto-Oncogene (RET), Platelet Derived Growth Factor Receptor Alpha (PDGFRA), KIT Proto-Oncogene (KIT), MET Proto-Oncogene (MET), and anaplastic lymphoma kinase (ALK) independently correlate with decreased overall survival and event free survival of pediatric neuroblastoma. The multikinase inhibitor sitravatinib targets DDR2, RET, PDGFRA, KIT, and MET with low nanomolar activity and we therefore tested its efficacy against orthotopic and syngeneic tumor models. Sitravatinib markedly reduced cell proliferation and migration in vitro independently of N-Myc proto-oncogene (MYCN), ALK, or c-Myc proto-oncogene status and inhibited proliferation and metastasis of human orthotopic xenografts. Oral administration of sitravatinib to homozygous Th-MYCN transgenic mice (Th-MYCN+/+) after tumor initiation completely arrested further tumor development with no mice dying of disease while maintained on sitravatinib treatment (control cohort 57 days median time to sacrifice). Among these top kinases, DDR2 expression has the strongest correlation with poor survival and high stage at diagnosis and the highest sensitivity to the drug. We confirmed on-target inhibition of collagen-mediated activation of DDR2. Genetic knockdown of DDR2 partially phenocopies sitravatinib treatment, limiting tumor development and metastasis across tumor models. Analysis of single-cell sequencing data demonstrated that DDR2 is restricted to mesenchymal-type tumor subpopulations and is enriched in Schwann cell precursor subpopulations found in high-risk disease. These data define an unsuspected role for sitravatinib as a therapeutic agent in neuroblastoma and reveal a novel function for DDR2 as a driver of tumor growth and metastasis.
To provide a nonwoven fabric for skin care product, which has a massive feeling due to excellent anti-see-through property thereof, excellent flexibility, soft touch, and adhesion to the skin, a high-quality feeling due to compatibility of the massive feeling and flexibility that have conventionally been considered incompatible, and excellent visibility of cosmetics and dirt wiped off.SOLUTION: A nonwoven fabric for a skin care product is a nonwoven fabric that contains 50 mass% or more of a polyester fiber having an average single fiber diameter of 1 to 20 μm. Basis weight of the nonwoven fabric is 20 to 100 g/m2. An anti-see-through index of the nonwoven fabric in a wet state is 65 or higher. An anti-see-through index with respect to the basis weight of the nonwoven fabric in the wet state is 1.3 or higher. The polyester fiber is a core-sheath conjugate fiber having a core component and a sheath component. A mass ratio between the core component and the sheath component is 50 to 95 to 50 to 5. The core component contains 5 to 30 mass% of inorganic particles. The sheath component contains 3 mass% or less of inorganic particles.SELECTED DRAWING: None
This is a prospective, randomised, control trial of 50 participants. Twenty five patients in each arm. Twenty five patients undergo standard pterygium excision with the fibrin glue (Tissucol) conjunctival autograft . Twenty five patients undergo pterygium surgery with fibrin glue (Tissucol), and subconjunctival injection of 0.1 ml of Tranilast 1.0% in the head of pterygium 30 days before surgery. Participants will be reviewed, selected, and consented on a pre-assessment day. Surgery will be performed 4 at a time on an all day surgery operating list. Randomisation of the surgery type will be done at the time of surgery after the pterygium has been excised and the autograft taken. The surgeries will perform by a single surgeon (Almeida Jr, GC). Follow-up will occur at week 1,4, 26, 52. Slit lamp examination will indicate pterygium recurrence. Corneal recurrence will consider when it 0.5 mm of invaded conjunctival tissue,in the clear cornea from the anatomical limbus. The conjunctival recurrence will consider of any size conjunctive fibrovascular invasion inside the graft. The localization and of immunohistochemical will be perform for TGF-B.
MMF will be prescribed at a starting dose of 1.5 g/day and increased to 2 g/day at week 4 (if body weight ≥ 45 kg) and continue the same dose until week 24. After week 24, MMF will be lowered to 1.5 g/day.
Patients undergo a clinical breast examination and a diagnostic mammogram with or without targeted breast ultrasound to the index cancer as part of their standard of care preoperative work-up. As part of the research study, patients receive contrast agent IV and then undergo a CESM with DBT over 30 minutes. Patients also receive a contrast agent, gadolinium, IV and undergo bilateral breast CE-MRI over 10 minutes.
Screening for alcohol use and substances of abuse in the emergency and trauma settings is critical for both effective current treatment of the presenting clinical issue and prevention of future incidents. Identification, engagement and treatment of substance use disorders decreased trauma and emergency department visits and medical comorbidities (Bertholet et al., 2005; Kaner et al., 2007). To ensure consistent documentation of alcohol and substance use, the emergency medicine is initiating a new standard of care for substance use screening: the use of a brief self-evaluation questionnaire on alcohol, tobacco and illicit substance use to be completed in triage. This questionnaire will allow emergency medicine patients presenting to the emergency room. This research study will perform a chart review on all self-evaluation questionnaires on alcohol, tobacco and substance use to determine the prevalence of use of specific substances in this patient population and associated demographic predictors and medical comorbidities. This study will also review medical records after one year of the index emergency room visit to establish rates or re-presentation and hospitalization correlated with different substance use.
All patients were to undergo all 4 diagnostic modalities, and each of these was compared to the consensus clinical diagnosis. Readers of each modality were blinded to the results of the other 3.